Thursday, December 13, 2007

glaxosmithkline Presents Innovative Neuroscience Pipeline (press release) - Newtown,PA,USA
Ofatumumab (humax-CD20), a promising monoclonal antibody, will move into phase II development early in 2008, exploring its potential in patients with ...
See all stories on this topic

Danish shares close sharply lower as Wall Street opens down UPDATE - USA
The biotech company said it expects to begin a phase II study of its Ofatumumab (humax-CD20R) treatment for relapsing remitting multiple sclerosis (RRMS) in ...
See all stories on this topic


Post a Comment

Links to this post:

Create a Link

<< Home